IVERIC bio Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $39.95
- Today's High:
- $39.95
- Open Price:
- $39.95
- 52W Low:
- $14.8
- 52W High:
- $39.99
- Prev. Close:
- $39.95
- Volume:
- 0
Company Statistics
- Market Cap.:
- $5.51 billion
- Book Value:
- 3.476
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $-117012000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -29.64%
- Return on Equity TTM:
- -55.02%
Company Profile
IVERIC bio Inc had its IPO on 2013-09-25 under the ticker symbol ISEE.
The company operates in the Healthcare sector and Biotechnology & Medical Research industry. IVERIC bio Inc has a staff strength of 163 employees.
Stock update
Shares of IVERIC bio Inc opened at $39.95 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $39.95 - $39.95, and closed at $39.95.
This is a 0% increase from the previous day's closing price.
A total volume of 0 shares were traded at the close of the day’s session.
In the last one week, shares of IVERIC bio Inc have increased by +1.55%.
IVERIC bio Inc's Key Ratios
IVERIC bio Inc has a market cap of $5.51 billion, indicating a price to book ratio of 3.805 and a price to sales ratio of 0.
In the last 12-months IVERIC bio Inc’s revenue was $0 with a gross profit of $-117012000 and an EBITDA of $-228890000. The EBITDA ratio measures IVERIC bio Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, IVERIC bio Inc’s operating margin was 0% while its return on assets stood at -29.64% with a return of equity of -55.02%.
In Q1, IVERIC bio Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
IVERIC bio Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.78 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into IVERIC bio Inc’s profitability.
IVERIC bio Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -5.6658. Its price to sales ratio in the trailing 12-months stood at 0.
IVERIC bio Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $613.41 million
- Total Liabilities
- $39.37 million
- Operating Cash Flow
- $39.27 million
- Capital Expenditure
- $233000
- Dividend Payout Ratio
- 0%
IVERIC bio Inc ended 2024 with $613.41 million in total assets and $0 in total liabilities. Its intangible assets were valued at $613.41 million while shareholder equity stood at $477.05 million.
IVERIC bio Inc ended 2024 with $0 in deferred long-term liabilities, $39.37 million in other current liabilities, 137000.00 in common stock, $-937035000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $467.57 million and cash and short-term investments were $599.92 million. The company’s total short-term debt was $774,000 while long-term debt stood at $96.99 million.
IVERIC bio Inc’s total current assets stands at $611.54 million while long-term investments were $0 and short-term investments were $132.35 million. Its net receivables were $0 compared to accounts payable of $18.03 million and inventory worth $0.
In 2024, IVERIC bio Inc's operating cash flow was $39.27 million while its capital expenditure stood at $233000.
Comparatively, IVERIC bio Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $39.95
- 52-Week High
- $39.99
- 52-Week Low
- $14.8
- Analyst Target Price
- $39.1
IVERIC bio Inc stock is currently trading at $39.95 per share. It touched a 52-week high of $39.99 and a 52-week low of $39.99. Analysts tracking the stock have a 12-month average target price of $39.1.
Its 50-day moving average was $38.17 and 200-day moving average was $26.21 The short ratio stood at 5.25 indicating a short percent outstanding of 0%.
Around 65.8% of the company’s stock are held by insiders while 10936.4% are held by institutions.
Frequently Asked Questions About IVERIC bio Inc
Similar Industry Stocks (Biotechnology & Medical Research)
+25.16%
Most Active
Top Gainers
Top Losers
About
IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprises miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey. As of July 11, 2023, IVERIC bio, Inc. operates as a subsidiary of Astellas US Holding, Inc.